Hikma intros generic Banzel

Hikma is offering rufinamide oral suspension in a dosage strength of 40mg/mL.

The product is the generic of Eisai’s Banzel.

It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.

“We are very pleased to launch a generic version of this important medicine in the US,” said Brian Hoffmann, president of Hikma Generics. "This launch further diversifies our portfolio of products and demonstrates our ability to successfully litigate patents, improving patients’ access to high-quality medicines.”

Rufinamide oral suspension had a market value of approximately $125 million in the 12 months ending September 2020, according to IQVIA.